

**IN THE UNITED STATES BANKRUPTCY COURT
FOR THE DISTRICT OF DELAWARE**

In re:

INSYS THERAPEUTICS, INC., *et al.*,

Liquidating Debtors.¹

Chapter 11

Case No. 19-11292 (BLS)

(Jointly Administered)

Re: D.I. 2075

**FINAL DECREE CLOSING SUBSIDIARY CASES
AND GRANTING RELATED RELIEF**

Upon the motion (the “Motion”),² of William Henrich, in his capacity as liquidating trustee (the “Trustee”) of the Insys Liquidation Trust (the “Trust”), pursuant to §§ 105(a), 342(c), and 350(a) of chapter 11 of title 11 of the United States Code (the “Bankruptcy Code”), Rules 1005, 2002(n), and 3022 of the Federal Rules of Bankruptcy Procedure (the “Bankruptcy Rules”), and Rule 3022-1(a) of the Local Rules of the Bankruptcy Court for District of Delaware (the “Local Rules”), for a final decree closing the Subsidiary Cases and leaving open the Lead Case, all as more fully described in the Motion; and the Court having jurisdiction to consider the Motion and the relief requested therein in accordance with 28 U.S.C. §§ 157 and 1334, the *Amended Standing Order of Reference* dated February 29, 2012, and Section X(14) of the Plan, pursuant to which the Court retained jurisdiction to, among other things, enter a final decree closing the Debtors’ chapter 11 cases; and consideration of the Motion and the relief requested therein being a core proceeding pursuant to 28 U.S.C. § 157(b); and venue being proper before this Court pursuant to 28 U.S.C.

¹ The Liquidating Debtors in these cases, along with the last four digits of each Debtor’s federal tax identification number, are: Insys Therapeutics, Inc. (7886); IC Operations, LLC (9659), Insys Development Company, Inc. (3020); Insys Manufacturing, LLC (0789); Insys Pharma, Inc. (9410); IPSC, LLC (6577); and IPT 355, LLC (0155).

² Capitalized terms used herein and not otherwise defined herein shall have the meanings ascribed to such terms in the Motion.

§§ 1408 and 1409; and notice of the Motion having been given as provided in the Motion, and such notice having been adequate and appropriate under the circumstances, and it appearing that no other or further notice need be provided; and there being no objection to the Motion; and the Court having found and determined that the relief sought in the Motion is in the best interests of the Debtors, their estates, the Trust, its beneficiaries, creditors, and all parties in interest, and that the legal and factual bases set forth in the Motion establish just cause for the relief granted herein; and after due deliberation and sufficient cause appearing therefor,

IT IS HEREBY ORDERED THAT

1. The Motion is granted as provided herein.
2. Pursuant to §§ 105(a) and 350(a) of the Bankruptcy Code, Bankruptcy Rule 3022, and Local Rule 3022-1(a), the following chapter 11 cases are hereby closed and a final decree (the “Final Decree”) is granted:

IC Operations LLC	19-11293
Insys Development Company, Inc.	19-11294
Insys Manufacturing, LLC	19-11295
Insys Pharma, Inc.	19-11296
IPSC, LLC	19-11297
IPT 355, LLC	19-11298
IC Operations LLC	19-11293
Insys Development Company, Inc.	19-11294

3. The chapter 11 case of Insys Therapeutics, Inc., Case No. 19-11292 (BLS) (the “Lead Case”), shall remain open pending further order of this Court and, from and after the date of entry of this Final Decree, all motions, notices, and other pleadings relating to any of the Debtors or Trust shall be filed in the Lead Case.

4. The Clerk of this Court shall enter this Final Decree individually on each of the dockets of the Subsidiary Cases and each of the dockets of the Subsidiary Cases shall be marked as “Closed.”

5. An entry shall be made on the docket of each of the Debtors' cases, other than that of the Subsidiary Cases, that is substantially similar to the following:

An order has been entered in accordance with Rule 3022-1 of the Local Rules of the United States Bankruptcy Court for the District of Delaware closing the chapter 11 cases of: IC Operations LLC, Insys Development Company, Inc., Insys Manufacturing, LLC, Insys Pharma, Inc., IPSC, LLC, IPT 355, LLC, IC Operations LLC, and Insys Development Company, Inc. All further pleadings and other papers shall be filed in and all further docket entries shall be made in the chapter 11 case of Insys Therapeutics, Inc., Case No. 19-11292 (JTD).

6. Notwithstanding the possible application of Bankruptcy Rules 7062, 9014 or otherwise, the terms and conditions of this Final Decree shall be immediately effective and enforceable upon its entry.

7. After the Subsidiary Cases are closed, the Trustee shall not be required to file post-confirmation reports in those cases for periods subsequent to closing of the Subsidiary Cases and no U.S. Trustee fees shall be assessed for periods subsequent to the closing of the Subsidiary Cases unless those cases are reopened.

8. The Trust shall continue to pay U.S. Trustee Fees solely with respect to disbursements made in the Lead Case.

9. The Trust shall, within 30 days after entry of this Final Decree, (a) pay all fees due and payable pursuant to 28 U.S.C. § 1930(a)(6). Entry of this Final Decree is without prejudice to the rights of the U.S. Trustee to reopen those Chapter 11 Cases closed hereby to seek appropriate relief in the event of an unresolved dispute over the payment of fees pursuant to 28 U.S.C. § 1930(a)(6) or the post-confirmation reports.

10. The Trust shall provide the U.S. Trustee all quarterly reports not already filed with respect to the Chapter 11 Cases of the Subsidiary Debtors, including reports for any partial quarter within 21 days after entry of this Order.

11. Entry of this Final Decree (a) is without prejudice to the rights of the Trust (and the Trustee) to commence, prosecute, and/or resolve any claim or cause of action against any party or object to or resolve claims filed against any of the Debtors as provided in the Plan, (b) is without prejudice to the rights, claims and defenses of any creditor, defendant or any other party in interest with respect to any claim or cause of action, and (c) shall have no effect whatsoever on any contested matter, adversary proceeding, or other matters pending before this Court, or which may be brought before this Court by any party, in each case, subject to the terms of the Plan and the Confirmation Order.

12. Notwithstanding entry of this Final Decree, as provided in the Plan, the Trustee shall be entitled to prosecute claims and defenses, make distributions, and attend to other wind-down affairs on behalf of the Trust and otherwise administer the Trust as if the estates of the Debtors in the Subsidiary Cases continued to exist solely for these purposes.

13. Notwithstanding the entry of this Final Decree or § 550(f) of the Bankruptcy Code, the closing of the Subsidiary Cases shall not affect the rights of the Trust or the Trustee to commence or maintain any action or proceeding, including without limitation actions to recover from any transferee or any subsequent transferee, in each case, subject to the terms of and as provided in the Plan and the Confirmation Order.

14. Following entry of this Final Decree, the caption for the Lead Case shall read as follows:

In re:	:	Chapter 11
INSYS THERAPEUTICS, INC.,	:	Case No. 19-11292 (BLS)
Liquidating Debtor.	:	

15. Notwithstanding entry of this Final Decree, the requirements of Local Rules 2002-1(e)(ix) and 3022-1(a)(ii) are waived with respect to the Subsidiary Cases, provided that the Trustee shall file a final report in accordance with Local Rule 3022-1(a)(ii) with respect to the consolidated Debtors as soon as reasonably practicable upon entry of an order closing the Lead Case.


16. The Trustee is authorized to take all actions necessary to effectuate the relief granted in this Final Decree.

17. Entry of this Final Decree and the closing of the Subsidiary Cases is for administrative purposes only and shall not create or prejudice any right, claim, defense or cause of action by or of a creditor, defendant or other party in interest in any other regard.

18. Entry of this Final Decree is without prejudice to the rights of any party in interest to seek to reopen any of the Subsidiary Cases for cause shown.

19. This Court shall retain jurisdiction to hear and determine all matters arising from or related to the implementation, interpretation and/or enforcement of this Final Decree.

Dated: December 15th, 2025
Wilmington, Delaware


 BRENDAN L. SHANNON
 UNITED STATES BANKRUPTCY JUDGE